Video

The Importance of Diverse Clinical Trials in Cancer

Author(s):

Donna Cryer, CEO and president of the Global Liver Institute, discusses the importance of having diverse clinical trials in cancer care.

Donna Cryer, CEO and president of the Global Liver Institute, discusses the importance of having diverse clinical trials in cancer care.

While patients may not often be aware of clinical trials, it might be the best treatment option for many of them. It is crucial that these patients talk to other patients who were on clinical trials, as well as their health care providers to better understand the process and become more comfortable with them.

Also, it is crucial that minorities and people around the world of different ethnic backgrounds participate in clinical trials so that when a therapy is approved, its efficacy has been proven for a variety of different genetic makeups.

Related Videos
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.